{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:24:37Z","timestamp":1789428277333,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA0909600"],"award-info":[{"award-number":["2021YFA0909600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004773","name":"Henan University","doi-asserted-by":"publisher","award":["KFGS24003"],"award-info":[{"award-number":["KFGS24003"]}],"id":[{"id":"10.13039\/501100004773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["JQRC2025015"],"award-info":[{"award-number":["JQRC2025015"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515010083"],"award-info":[{"award-number":["2025A1515010083"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515110426"],"award-info":[{"award-number":["2023A1515110426"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"publisher","award":["242102311032"],"award-info":[{"award-number":["242102311032"]}],"id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jare.2026.02.005","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:59:24Z","timestamp":1770685164000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic Antitumor Activity and Neuroprotective Effects of FGF1\/FGFR Inhibition with Oxaliplatin Chemotherapy"],"prefix":"10.1016","author":[{"given":"Cuiqing","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youfeng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2026.02.005_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1105484","article-title":"Emerging role of non-coding RNAs in resistance to platinum-based anti-cancer agents in lung cancer","volume":"14","author":"Mondal","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jare.2026.02.005_b0010","doi-asserted-by":"crossref","first-page":"15410","DOI":"10.3390\/ijms232315410","article-title":"Revisiting the anti-cancer toxicity of clinically approved platinating derivatives","volume":"23","author":"Forgie","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jare.2026.02.005_b0015","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/ijms24021548","article-title":"Will the interactions of some platinum (II)-based drugs with B-vitamins reduce their therapeutic effect in cancer patients? Comparison of chemotherapeutic agents such as cisplatin, carboplatin and oxaliplatin-a review","volume":"24","author":"Szefler","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jare.2026.02.005_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120789","article-title":"Repurposing FDA-approved drugs against the toxicity of platinum-based anticancer drugs","volume":"305","author":"Famurewa","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.jare.2026.02.005_b0025","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.22.01142","article-title":"Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III, randomized study","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2026.02.005_b0030","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/cas.16110","article-title":"Phase I trial of apatinib and paclitaxel+oxaliplatin+5-FU\/levoleucovorin for treatment-na\u00efve advanced gastric cancer","volume":"115","author":"Zhao","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jare.2026.02.005_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1079707","article-title":"The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer","volume":"13","author":"Bi","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jare.2026.02.005_b0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2024.02.025","article-title":"Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment","volume":"368","author":"Cao","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.jare.2026.02.005_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122235","article-title":"Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer","volume":"301","author":"Jiang","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.jare.2026.02.005_b0050","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12073","article-title":"Small extracellular vesicles ameliorate peripheral neuropathy and enhance chemotherapy of oxaliplatin on ovarian cancer","volume":"10","author":"Zhang","year":"2021","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.jare.2026.02.005_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116310","article-title":"Deciphering drug resistance in gastric cancer: potential mechanisms and future perspectives","volume":"173","author":"Liu","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jare.2026.02.005_b0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drup.2018.07.001","article-title":"Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation","volume":"39","author":"Cecchin","year":"2018","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jare.2026.02.005_b0065","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/bja\/aex229","article-title":"Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review","volume":"119","author":"Flatters","year":"2017","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jare.2026.02.005_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1231401","article-title":"Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jare.2026.02.005_b0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13046-021-02141-z","article-title":"Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development","volume":"40","author":"Yang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jare.2026.02.005_b0080","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.01.001","article-title":"Oxaliplatin-related neurotoxicity: how and why?","volume":"59","author":"Pasetto","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jare.2026.02.005_b0085","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1002\/cncr.25889","article-title":"Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma","volume":"117","author":"Sun","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jare.2026.02.005_b0090","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/cncr.23489","article-title":"Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study","volume":"112","author":"Asnacios","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jare.2026.02.005_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.11.006","article-title":"Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine?","volume":"179","author":"Roth","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jare.2026.02.005_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100638","article-title":"Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?","volume":"7","author":"R\u00e9mond","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.jare.2026.02.005_b0105","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s43440-020-00106-1","article-title":"Chemotherapy-induced peripheral neuropathy-part 2: focus on the prevention of oxaliplatin-induced neurotoxicity","volume":"72","author":"Sa\u0142at","year":"2020","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jare.2026.02.005_b0110","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/cancers12061370","article-title":"Management of oxaliplatin-induced peripheral sensory neuropathy","volume":"12","author":"Cavaletti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2026.02.005_b0115","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12964-023-01284-0","article-title":"Fibroblast growth factor signaling in axons: from development to disease","volume":"21","author":"Tom\u00e9","year":"2023","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.jare.2026.02.005_b0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.semcdb.2015.09.021","article-title":"Metabolic fibroblast growth factors (FGFs): mediators of energy homeostasis","volume":"53","author":"Markan","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.jare.2026.02.005_b0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"10.1016\/j.jare.2026.02.005_b0130","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/cells10040884","article-title":"FGF\/FGFR pathways in multiple sclerosis and in its disease models","volume":"10","author":"Rajendran","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jare.2026.02.005_b0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","article-title":"Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment","volume":"22","author":"Ruan","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jare.2026.02.005_b0140","doi-asserted-by":"crossref","first-page":"e2079","DOI":"10.1038\/cddis.2016.2","article-title":"FGF1 C-terminal domain and phosphorylation regulate intracrine FGF1 signaling for its neurotrophic and anti-apoptotic activities","volume":"7","author":"Delmas","year":"2016","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jare.2026.02.005_b0145","doi-asserted-by":"crossref","first-page":"10292","DOI":"10.3390\/ijms241210292","article-title":"Roles of fibroblast growth factors in the axon guidance","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jare.2026.02.005_b0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/dvdy.21388","article-title":"Functional evolutionary history of the mouse Fgf gene family","volume":"237","author":"Itoh","year":"2008","journal-title":"Dev Dyn"},{"key":"10.1016\/j.jare.2026.02.005_b0155","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0168-8278(97)80085-2","article-title":"Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism","volume":"27","author":"Kin","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2026.02.005_b0160","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/s41416-022-01899-z","article-title":"Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer","volume":"127","author":"Nicholson","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jare.2026.02.005_b0165","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41416-022-01902-7","article-title":"LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1\/FGFR axis","volume":"127","author":"Xie","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jare.2026.02.005_b0170","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/2319-4170.113226","article-title":"Stem cell-based therapy in neural repair","volume":"36","author":"Hsu","year":"2013","journal-title":"Biomed J"},{"key":"10.1016\/j.jare.2026.02.005_b0175","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neuroscience.2007.08.024","article-title":"Activation of fibroblast growth factor receptor by axotomy, through downstream p38 in dorsal root ganglion, contributes to neuropathic pain","volume":"150","author":"Yamanaka","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.jare.2026.02.005_b0180","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nature18600","article-title":"A combinatorial strategy for treating KRAS-mutant lung cancer","volume":"534","author":"Manchado","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.02.005_b0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2026.02.005_b0190","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/2326-6066.CIR-22-0197","article-title":"NET-triggered NLRP3 activation and IL18 release drive oxaliplatin-induced peripheral neuropathy","volume":"10","author":"Lin","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jare.2026.02.005_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101677","article-title":"Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis","volume":"36","author":"Fang","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.jare.2026.02.005_b0200","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.neuroimage.2017.09.053","article-title":"Whole brain g-ratio mapping using myelin water imaging (MWI) and neurite orientation dispersion and density imaging (NODDI)","volume":"182","author":"Jung","year":"2018","journal-title":"Neuroimage"},{"key":"10.1016\/j.jare.2026.02.005_b0205","doi-asserted-by":"crossref","DOI":"10.20517\/mtod.2022.38","article-title":"Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms","volume":"3","author":"Lugari","year":"2023","journal-title":"mtod"},{"key":"10.1016\/j.jare.2026.02.005_b0210","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/jcb.30267","article-title":"Differential effects of 5-fluorouracil and oxaliplatin on autophagy in chemoresistant colorectal cancer cells","volume":"123","author":"Zitkute","year":"2022","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.jare.2026.02.005_b0215","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2021.03.028","article-title":"First-line liposomal irinotecan with oxaliplatin, 5-fluorouraciland leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: a phase I\/II study","volume":"151","author":"Wainberg","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jare.2026.02.005_b0220","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jare.2026.02.005_b0225","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3892\/ol.2013.1263","article-title":"Gemcitabine plus oxaliplatin for the treatment of leptomeningeal metastases of non-small cell lung cancer: a case report and review of the literature","volume":"5","author":"Bai","year":"2013","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jare.2026.02.005_b0230","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.critrevonc.2013.08.009","article-title":"Oxaliplatin induced-neuropathy in digestive tumors","volume":"89","author":"Sereno","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jare.2026.02.005_b0235","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cytogfr.2020.05.004","article-title":"Intracellular partners of fibroblast growth factors 1 and 2 - implications for functions","volume":"57","author":"Sluzalska","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jare.2026.02.005_b0240","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/10408360701713120","article-title":"FGF-1: from biology through engineering to potential medical applications","volume":"45","author":"Zakrzewska","year":"2008","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.jare.2026.02.005_b0245","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1677\/erc.1.00535","article-title":"The role of fibroblast growth factors and their receptors in prostate cancer","volume":"11","author":"Kwabi-Addo","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jare.2026.02.005_b0250","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s40478-014-0168-9","article-title":"Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination","volume":"2","author":"Mohan","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.jare.2026.02.005_b0255","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.26679","article-title":"Fibroblast growth factor signaling in liver carcinogenesis","volume":"59","author":"Sandhu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jare.2026.02.005_b0260","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jare.2026.02.005_b0265","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13009","article-title":"Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif"},{"key":"10.1016\/j.jare.2026.02.005_b0270","article-title":"Advances of fibroblast growth factor\/receptor signaling pathway in hepatocellular carcinoma and its pharmacotherapeutic targets","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.jare.2026.02.005_b0275","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.7150\/thno.68972","article-title":"Sun JZ et al: FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jare.2026.02.005_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117897","article-title":"Current insights and barriers in FGFR-mediated signaling in lung cancer","volume":"296","author":"Liu","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jare.2026.02.005_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1441935","article-title":"Antagonistic roles of cGAS\/STING signaling in colorectal cancer chemotherapy","volume":"14","author":"Liang","year":"2024","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.jare.2026.02.005_b0290","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/2326-6066.CIR-22-0197","article-title":"NET-triggered NLRP3 activation and IL18 release drive oxaliplatin-induced peripheral neuropathy","volume":"10","author":"Lin","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jare.2026.02.005_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1572604","article-title":"Erdafitinib diminishes LPS-mediated neuroinflammatory responses through NLRP3 in wild-type mice","volume":"16","author":"Lee","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jare.2026.02.005_b0300","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jare.2026.02.005_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.860985","article-title":"Signaling pathway and small-molecule drug discovery of FGFR: a comprehensive review","volume":"10","author":"Zheng","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.jare.2026.02.005_b0310","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/PO.20.00110","article-title":"Remarkable response to erdafitinib in metastatic lung adenocarcinoma with FGFR fusion","volume":"4","author":"Urrutia Argueta","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jare.2026.02.005_b0315","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.7150\/thno.68972","article-title":"FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jare.2026.02.005_b0320","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1186\/s12967-023-04450-7","article-title":"Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs","volume":"21","author":"Pace","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.jare.2026.02.005_b0325","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14737140.2023.2192930","article-title":"Pemigatinib for the treatment of myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"23","author":"Freyer","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jare.2026.02.005_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116845","article-title":"Targeting fibroblast growth factor receptor (FGFR) with inhibitors in head and neck cancers: their roles, mechanisms and challenges","volume":"235","author":"Luo","year":"2025","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.jare.2026.02.005_b0335","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.jare.2026.02.005_b0340","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","article-title":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jare.2026.02.005_b0345","article-title":"Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123226001360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123226001360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:07:32Z","timestamp":1771391252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123226001360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":69,"alternative-id":["S2090123226001360"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2026.02.005","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic Antitumor Activity and Neuroprotective Effects of FGF1\/FGFR Inhibition with Oxaliplatin Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2026.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}